AFMD affimed.com: Long-Term Debt to Capital Coefficient

Affimed is forging strategic alliances with global pharmaceutical leaders to develop cancer immunotherapies. Affimed implements unique antibodies that compel the body to destroy neoplasms, protecting its proprietary developments with patents. The operating model relies on outsourcing drug production to external contractors, which reduces costs. This price action chart for Affimed (AFMD) on GURU.Markets shows a value of 0.00, illustrating the asset's market trend.

The long-term debt-to-equity ratio compares liabilities with maturities exceeding one year against the market value of assets. For Affimed (AFMD), this balance is critical when financing the development of the ROCK platform and implementing partnerships with pharma behemoths. By analyzing the history of long-term debt relative to equity, an investor determines the company's degree of financial autonomy. A decrease in this metric minimizes default risk but may signal conservative management. A stable trend confirms the resilience of the business's fundamental structure.